CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN If approved by the European Commission, ELZONRIS will be the first approved treatment f...